JP2010539155A - ペルハリジン - Google Patents

ペルハリジン Download PDF

Info

Publication number
JP2010539155A
JP2010539155A JP2010524600A JP2010524600A JP2010539155A JP 2010539155 A JP2010539155 A JP 2010539155A JP 2010524600 A JP2010524600 A JP 2010524600A JP 2010524600 A JP2010524600 A JP 2010524600A JP 2010539155 A JP2010539155 A JP 2010539155A
Authority
JP
Japan
Prior art keywords
group
groups
compound
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010524600A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539155A5 (enExample
Inventor
マイヤー，ローラン
ベッタイブ，カリマ
ガロン，エルベ
デモンジュ，リュック
オーマタ，ナッシマ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite Paris Descartes
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite Paris Descartes filed Critical Centre National de la Recherche Scientifique CNRS
Publication of JP2010539155A publication Critical patent/JP2010539155A/ja
Publication of JP2010539155A5 publication Critical patent/JP2010539155A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2010524600A 2007-09-12 2008-09-12 ペルハリジン Pending JP2010539155A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/IB2007/003655 WO2009034411A1 (en) 2007-09-12 2007-09-12 Perharidines as cdk inhibitors
PCT/IB2008/003106 WO2009034475A2 (en) 2007-09-12 2008-09-12 Perharidines as cdk inhibitors

Publications (2)

Publication Number Publication Date
JP2010539155A true JP2010539155A (ja) 2010-12-16
JP2010539155A5 JP2010539155A5 (enExample) 2012-03-22

Family

ID=39773126

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010524600A Pending JP2010539155A (ja) 2007-09-12 2008-09-12 ペルハリジン

Country Status (10)

Country Link
US (1) US8450342B2 (enExample)
EP (1) EP2185557A2 (enExample)
JP (1) JP2010539155A (enExample)
KR (1) KR20100075907A (enExample)
CN (1) CN101809020A (enExample)
BR (1) BRPI0816799A2 (enExample)
CA (1) CA2699040A1 (enExample)
MX (1) MX2010002477A (enExample)
RU (1) RU2498984C2 (enExample)
WO (2) WO2009034411A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059634A1 (en) 2011-10-20 2013-04-25 The Regents Of The University Of California Use of cdk9 inhibitors to reduce cartilage degradation
CN105481858B (zh) * 2014-10-11 2019-05-17 上海医药集团股份有限公司 一种含氮稠杂环化合物、其制备方法、组合物及应用
ES3004338T3 (en) 2018-09-10 2025-03-12 Mirati Therapeutics Inc Combination therapies
CN111217814B (zh) * 2018-11-26 2022-08-26 天津科技大学 一类联哌啶衍生物及其作为抗肿瘤药物的应用
WO2021121390A1 (zh) 2019-12-20 2021-06-24 苏州信诺维医药科技股份有限公司 杂环化合物及其药物组合物、制备方法、中间体和应用
GB202108572D0 (en) * 2021-06-16 2021-07-28 Carrick Therapeutics Ltd Therapeutic compounds and their use
CN115104576A (zh) * 2022-07-12 2022-09-27 河北医科大学 Cdk5调控eEF2在糖尿病肾病防治中的操作方法
CN118598874A (zh) * 2024-05-21 2024-09-06 江南大学 一种取代的9h嘌呤类化合物、药物组合物及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510327A (ja) * 1999-09-30 2003-03-18 ニューロジェン・コーポレーション 特定のアルキレンジアミンで置換された複素環
WO2006061380A2 (en) * 2004-12-09 2006-06-15 Altana Pharma Ag SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU566842A1 (ru) * 1976-01-06 1977-07-30 Донецкое Отделение Физико-Органической Химии Института Физической Химии Им.Л.В.Писаржевского Ан Украинской Сср Способ получени замещенных имидазопиридинов
UA74593C2 (en) * 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
EP1352910A1 (en) * 2002-04-10 2003-10-15 Grünenthal GmbH New analogs of nitrobenzylthioinosine
US7718651B2 (en) * 2002-07-02 2010-05-18 Southern Research Institute Inhibitors of FtsZ and uses thereof
CA2576159A1 (en) * 2004-08-27 2006-03-02 Cyclacel Limited Purine and pyrimidine cdk inhibitors and their use for the treatment of autoimmune diseases
TW200616624A (en) * 2004-09-09 2006-06-01 Solvay Pharm Bv 2-substituted-1-deaza purine derivatives with adenosine receptor modulating activity

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003510327A (ja) * 1999-09-30 2003-03-18 ニューロジェン・コーポレーション 特定のアルキレンジアミンで置換された複素環
WO2006061380A2 (en) * 2004-12-09 2006-06-15 Altana Pharma Ag SUBSTITUTED IMIDAZO[4,5-b]PYRIDINES AS INHIBITORS OF GASTRIC ACID SECRETION

Also Published As

Publication number Publication date
EP2185557A2 (en) 2010-05-19
RU2498984C2 (ru) 2013-11-20
CN101809020A (zh) 2010-08-18
US8450342B2 (en) 2013-05-28
CA2699040A1 (en) 2009-03-19
WO2009034475A3 (en) 2009-08-13
WO2009034411A1 (en) 2009-03-19
MX2010002477A (es) 2010-08-09
BRPI0816799A2 (pt) 2015-03-03
WO2009034475A2 (en) 2009-03-19
KR20100075907A (ko) 2010-07-05
RU2010108507A (ru) 2011-10-20
US20100280065A1 (en) 2010-11-04

Similar Documents

Publication Publication Date Title
US7576091B2 (en) Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases
JP6959248B2 (ja) 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体
JP2010539155A (ja) ペルハリジン
JP5756176B2 (ja) ６−シクロアルキル−１，５−ジヒドロ−ピラゾロ（３，４−ｄ）ピリミジ−４−オン誘導体及びｐｄｅ９ａ阻害剤としてのその使用
JP6661049B2 (ja) Ｃｄｋ阻害剤としてのヘテロ環置換ピリジノピリミジノン誘導体およびその薬学的に許容される塩、並びに、医薬品組成物
PL220952B1 (pl) 2-(Pirydyn-2-yloamino)pirydo[2,3-d]pirymidyn-7-ony
JP2007500178A (ja) プロテインキナーゼ阻害剤としてのピリジニルアミノ−ピリミジン誘導体
JP4570362B2 (ja) 置換した２−ピリジニル−６，７，８，９−テトラヒドロピリミド［１，２−ａ］ピリミジン−４−オンおよび７−ピリジニル−２，３−ジヒドロイミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）オン誘導体
KR20140010036A (ko) ６­사이클로부틸­１，５­디하이드로­피라졸로［３，４­ｄ］피리미딘­４­온 유도체 및 이의 ｐｄｅ９ａ 억제제로서의 용도
JP2020504747A (ja) ベンズイミダゾール誘導体、調製方法およびそれらの使用
JP5124471B2 (ja) 置換二環式ピリミドン誘導体
JP2020530833A (ja) ピロロピリミジン及びピロロピリジン誘導体
JP4484524B2 (ja) １−［アルキル］、１−［（ヘテロアリール）アルキル］および１−［（アリール）アルキル］−７−（ピリミジン−４−イル）−イミダゾ［１，２−ａ］ピリミジン−５（１Ｈ）−オン誘導体
WO2011103289A2 (en) Imidazole-2, 4-dione inhibitors of casein kinase 1
US9957273B2 (en) 5-substituted 7- [4-(2-pyridyl)phenylmethylamino] -3-isopropylpyrazolo4,3-D]pyrimidine derivatives, use thereof as medicaments, and pharmaceutical compositions
Mishra et al. Design, synthesis and characterization of 2-pyridone derivatives as C-Jun N-terminal Kinases (JNKs) signaling pathway inhibitors
JP7157084B2 (ja) キナーゼＪＡＫ阻害剤としてのピラゾロ［１，５－ａ］ピリミジン誘導体
Benchat et al. Impact of Dimroth Rearrangement on Anti-Tuberculosis Activity of 3-Armed-Imidazo [1, 2-] Pyrimidines Imp (-Pyridines) Ip
CZ306987B6 (cs) 2,6-disubstituované puriny pro použití jako léčiva a farmaceutické přípravky je obsahující
CN106336412A (zh) 作为cdk4/6抑制剂的2-(n-氧化芳环-2基氨基)-吡咯并嘧啶及嘌呤类化合物
CZ306434B6 (cs) 2,6-disubstituované puriny pro použití jako léčiva, a farmaceutické přípravky
WO2014141118A1 (en) Imidazo[4,5-c]quinoline derivatives and uses thereof
CN115667263A (zh) 吡咯并[2,3-d]嘧啶衍生物
HK1178539B (en) 6-cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors
OA16302A (en) 6-Cycloalkyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as PDE9A inhibitors.

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130806

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130813

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130904

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130911

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140205